RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $182 Price Target

Benzinga · 10/21 14:01
RBC Capital analyst Brian Abrahams reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $182 price target.